(Q46092379)

19 December 2017

title

Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). (English)

1 reference

19 December 2017

1 reference

11

Katherine K Matthay

1 reference

19 December 2017

author name string

Paul A Fitzgerald

1

1 reference

19 December 2017

Robert E Goldsby

2

1 reference

19 December 2017

John P Huberty

3

1 reference

19 December 2017

David C Price

4

1 reference

19 December 2017

Randall A Hawkins

5

1 reference

19 December 2017

Janet J Veatch

6

1 reference

19 December 2017

Filemon Dela Cruz

7

1 reference

19 December 2017

Thierry M Jahan

8

1 reference

19 December 2017

Charles A Linker

9

1 reference

19 December 2017

Lloyd Damon

10

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

19 December 2017

Annals of the New York Academy of Sciences

published in

1 reference

19 December 2017

volume

1073

1 reference

19 December 2017

page(s)

465-490

1 reference

19 December 2017

Circumstances of discovery of phaeochromocytoma: a retrospective study of 41 consecutive patients.

cites work

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Increased expression of cyclooxygenase-2 in malignant pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

PET scan assessment of chemotherapy response in metastatic paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Functional imaging of endocrine tumors: role of positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Anatomical and functional imaging of metastatic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Mortality associated with pheochromocytoma in a large Swedish cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

An effective use of magnesium sulfate for intraoperative management of laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Partial adrenalectomy: the National Cancer Institute experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Bisphosphonates for treatment and prevention of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Expression of vascular endothelial growth factor (VEGF) and its cognate receptors in human pheochromocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Update on angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Nifedipine-induced morphological differentiation of rat pheochromocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Radiation therapy of metastatic pheochromocytoma: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Cyberknife radiosurgery for metastatic spine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

The myelodysplastic syndromes: diagnosis, molecular biology and risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131i] metaiodobenzylguanidine: Implications for the targeted radiotherapy of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1353.050

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1353.050

1 reference

19 December 2017

1 reference

19 December 2017